Evidence map›Paper›PMID 41466192›Full record

ArticleBMC nephrology2025

Serum ALCAM is a potential novel non-invasive marker for predicting the progression of IgA nephropathy.

Zengyuan Luo, Linlin Zhang, Zaiyu Wang, Qi Xiong, Jieyu Tang, Yongwen Yang, Xueling Hu, Huipeng Ge, Xiangcheng Xiao, Rong Tang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zengyuan Luo *Department of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Linlin Zhang *Department of Nephrology, Nanyang Central Hospital, Nanyang, 473000, China.
Zaiyu WangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Qi XiongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Jieyu TangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Yongwen YangDepartment of Laboratory, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xueling HuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Huipeng GeDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Xiangcheng XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China.
Rong TangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, 410008, China. tangrbsoon@126.com.
Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, China. linwei_610@126.com.

Funding

the Natural Science Foundation of Hunan Province 2022JJ30070
6 · The paper itself

Abstract

backgroundActivated leukocyte cell adhesion molecule (ALCAM) serves as an important effector that activates and traffics lymphocytes into tissues. The expression and role of ALCAM in IgA nephropathy (IgAN) remain unclear. Here, we aim to evaluate the expression and effect of ALCAM in IgAN patients.

methodsWe performed a prospective study including 71 IgAN patients, and 41 controls. Serum and uALCAM levels were evaluated. Renal expression of ALCAM and its ligand S100B were measured. The correlation of serum ALCAM with clinical data, renal pathology, and prognosis was analyzed. Cox regression analysis was conducted to identify independent factors associated with prognosis. Kaplan-Meier survival analysis was performed to explore the role of serum ALCAM.

resultsCirculating ALCAM levels were higher in IgAN patients than in controls. Serum ALCAM levels showed a positive correlation with proteinuria and renal pathology. Renal ALCAM expression was also elevated in IgAN patients. IgAN patients were divided into low and high ALCAM groups (< 4.76, and ≥ 4.76 ng/mL) based on the optimal cut-off value for predicting renal progression. The high ALCAM group exhibited more severe clinical parameters and renal pathology. High serum ALCAM level was an independent risk factor for IgAN progression. IgAN patients with high ALCAM level exhibited a lower cumulative renal survival rate compared to the low-level group.

conclusionsIn summary, serum ALCAM level in IgAN patients was elevated, which was consistent with clinical and pathological severity, and served as an independent risk factor and a promising novel predictor for the progression of IgAN. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Antigens, CDCell Adhesion Molecules, NeuronalFetal ProteinsGlomerulonephritis, IGAActivated-Leukocyte Cell Adhesion MoleculeAdultBiomarkersDisease ProgressionFemaleHumansKidneyMaleMiddle AgedPrognosisProspective StudiesActivated-Leukocyte Cell Adhesion MoleculeALCAM protein, humanAntigens, CDBiomarkersCell Adhesion Molecules, NeuronalFetal ProteinsALCAMIgA nephropathyMarkerProgressionRenal biopsy

Identifiers

PMID41466192
PMCPMC12750689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.